The FDA has approved tapentadol immediate-release tablets (from PriCara) for the relief of moderate-to-severe acute pain in adults ≥18 years of age. In clinical studies of over 2100 patients, tapentadol provided significant relief when compared to placebo. The studies included different patient groups such as those with pain associated with a bunionectomy, end stage joint disease, osteoarthritis of the hip or knee, or low back pain.

Tapentadol is both a mu-opioid agonist and norepinephrine reuptake inhibitor. It will be available in dosage strengths of 50mg, 75mg, and 100mg.

For more information call (800) 526-7736 or visit www.pricara.com.